
## Pinuccia Faviana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9232169/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Annals of Surgical Oncology, 2022, 29, 3405-3417.	0.7	16
2	Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. Endocrine, 2021, 72, 268-278.	1.1	10
3	Gastrin-Releasing Peptide Receptor in Low Grade Prostate Cancer: Can It Be a Better Predictor Than Prostate-Specific Membrane Antigen?. Frontiers in Oncology, 2021, 11, 650249.	1.3	13
4	Robotically assisted removal of pelvic splenosis fifty-six years after splenectomy: A case report. World Journal of Clinical Cases, 2021, 9, 2868-2873.	0.3	0
5	Multi-Dimensional Scaling Analysis of Key Regulatory Genes in Prostate Cancer Using the TCGA Database. Genes, 2021, 12, 1350.	1.0	2
6	Autologous fascial slings remain viable at long-term follow-up: a post cystectomy case report. BMC Urology, 2021, 21, 122.	0.6	1
7	Perioperative Morbidity Following Cytoreductive Surgery Combined with Intraperitoneal Chemohyperthermia in a Novel Italian Centre. European Journal of Surgical Oncology, 2020, 46, e160-e161.	0.5	Ο
8	Unusual Case of Pancreatic Adenocarcinoma with Bladder Metastasis. Medicina (Lithuania), 2020, 56, 708.	0.8	0
9	Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center. In Vivo, 2020, 34, 2061-2066.	0.6	3
10	C-MYC, HIF-1α, ERG, TKT, and GSTP1: an Axis in Prostate Cancer?. Pathology and Oncology Research, 2019, 25, 1423-1429.	0.9	11
11	EZH2 Expression in Intestinal Neuroendocrine Tumors. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 689-693.	0.6	7
12	Primary small cell carcinoma of the ureter. Medicine (United States), 2018, 97, e11113.	0.4	17
13	Thyroid peroxidase identified in human granulosa cells: another piece to the thyroid-ovary puzzle?. Gynecological Endocrinology, 2017, 33, 574-576.	0.7	28
14	Enhancer of zeste homolog 2 (EZH2) expression in G1 -G2 Pancreatic Neuroendocrine Tumor (pNET). Annals of Oncology, 2016, 27, iv21.	0.6	1
15	Enhancer of zest homolog 2 (EZH2) expression in well and moderately differentiated pancreatic neuroendocrine tumor (pNET). Annals of Oncology, 2016, 27, vi142.	0.6	2
16	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. BMC Cancer, 2015, 15, 874.	1.1	10
17	Prophylactic Central Compartment Lymph Node Dissection in Papillary Thyroid Carcinoma: Clinical Implications Derived From the First Prospective Randomized Controlled Single Institution Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1316-1324.	1.8	240
18	Lymphoepithelioma-like hepatocellular carcinoma: Case report and review of the literature. World Journal of Gastroenterology, 2015, 21, 10468.	1.4	16

Pinuccia Faviana

#	Article	IF	CITATIONS
19	A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. Pharmacogenomics, 2014, 15, 609-618.	0.6	10
20	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncology, 2014, 9, 205-214.	1.7	27
21	Primary Retroperitoneal Müllerian Adenocarcinoma: A Case Report and Literature Review. Case Reports in Oncology, 2013, 6, 616-621.	0.3	5
22	The Timing of Total Thyroidectomy in <i>RET</i> Gene Mutation Carriers Could Be Personalized and Safely Planned on the Basis of Serum Calcitonin: 18 Years Experience at One Single Center. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 426-435.	1.8	119
23	EZH2 Expression in Colorectal (CRC) Cancer: Single Nucleotide Polymorphism (SNP) Characterization and Correlation With Clinico-Pathological and Molecular Parameters. Annals of Oncology, 2012, 23, ix85.	0.6	Ο
24	Female Infertility Related to Thyroid Autoimmunity: The Ovarian Follicle Hypothesis. American Journal of Reproductive Immunology, 2011, 66, 108-114.	1.2	136
25	Image of the Month—Quiz Case. Archives of Surgery, 2010, 145, 99.	2.3	1
26	Thermal Ablation of Lung Tissue: In Vivo Experimental Comparison of Microwave and Radiofrequency. CardioVascular and Interventional Radiology, 2010, 33, 818-827.	0.9	52
27	CXC Chemokine Receptor 4 Immunodetection in the Follicular Variant of Papillary Thyroid Carcinoma: Comparison to Galectin-3 and Hector Battifora Mesothelial Cell-1. Thyroid, 2010, 20, 495-504.	2.4	24
28	A Ganglioneuroma with Features of a Thyroid Nodule: Intense Pain on Fine Needle Biopsy as a Diagnostic Clue. Thyroid, 2009, 19, 201-204.	2.4	7
29	Surgical Treatment of Low- and Intermediate-Risk Papillary Thyroid Cancer with Minimally Invasive Video-Assisted Thyroidectomy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1618-1622.	1.8	93
30	Prognostic Significance of Somatic <i>RET</i> Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 682-687.	1.8	478
31	BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocrine-Related Cancer, 2008, 15, 511-520.	1.6	139
32	Increased P2X7 Receptor Expression and Function in Thyroid Papillary Cancer: A New Potential Marker of the Disease?. Endocrinology, 2008, 149, 389-396.	1.4	123
33	Biological Role and Potential Therapeutic Targeting of the Chemokine Receptor CXCR4 in Undifferentiated Thyroid Cancer. Cancer Research, 2007, 67, 11821-11829.	0.4	100
34	Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity. Human Pathology, 2007, 38, 1482-1488.	1.1	18
35	Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hrthle cell thyroid lesions: results from a series of 505 consecutive patients. Clinical Endocrinology, 2006, 66, 061109020454002-???.	1.2	107
36	Nontender Submandibular Mass in a Middle-Aged Adult. Journal of Oral and Maxillofacial Surgery, 2006, 64, 683-690.	0.5	2

Ρινυς Γανιανά

#	Article	IF	CITATIONS
37	Biologic effects of radiofrequency thermal ablation on non–small cell lung cancer: Results of a pilot study. Journal of Thoracic and Cardiovascular Surgery, 2006, 131, 1002-1006.	0.4	53
38	Correlation between B-RAFV600E mutation and clinico–pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocrine-Related Cancer, 2006, 13, 455-464.	1.6	207
39	Percutaneous radiofrequency ablation of lung tumours: results in the mid-termâ~†. European Journal of Cardio-thoracic Surgery, 2006, 30, 177-183.	0.6	121
40	Treatment with Drugs Able to Reduce Iodine Efflux Significantly Increases the Intracellular Retention Time in Thyroid Cancer Cells Stably Transfected with Sodium Iodide Symporter Complementary Deoxyribonucleic Acid. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2389-2395.	1.8	41
41	Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. British Journal of Cancer, 2005, 93, 453-457.	2.9	69
42	Osteopontin Expression and Prognostic Significance in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 6459-6465.	3.2	98
43	Type I Interferons Modulate the Expression of Thyroid Peroxidase, Sodium/Iodide Symporter, and Thyroglobulin Genes in Primary Human Thyrocyte Cultures. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1156-1162.	1.8	53
44	Mitogenic Effects of the Up-Regulation of Minichromosome Maintenance Proteins in Anaplastic Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4703-4709.	1.8	38
45	All-Trans-Retinoic Acid Treatment Inhibits the Growth of Retinoic Acid Receptor Î <sup>2</sup> Messenger Ribonucleic Acid Expressing Thyroid Cancer Cell Lines but Does Not Reinduce the Expression of Thyroid-Specific Genes. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2403-2411.	1.8	41
46	Osteopontin Is Overexpressed in Human Papillary Thyroid Carcinomas and Enhances Thyroid Carcinoma Cell Invasiveness. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5270-5278.	1.8	71
47	RET/PTC3 Rearrangement and Thyroid Differentiation Gene Analysis in a Struma Ovarii Fortuitously Revealed by Elevated Serum Thyroglobulin Concentration. Thyroid, 2005, 15, 1355-1361.	2.4	25
48	Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. European Journal of Cancer, 2005, 41, 2828-2835.	1.3	45
49	Analysis of BRAF Point Mutation and RET/PTC Rearrangement Refines the Fine-Needle Aspiration Diagnosis of Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5175-5180.	1.8	252
50	Medullary and Papillary Tumors Are Frequently Associated in the Same Thyroid Gland without Evidence of Reciprocal Influence in Their Biologic Behavior. Thyroid, 2004, 14, 946-952.	2.4	60
51	Thyroid papillary carcinoma: preliminary evidence for a germ-line single nucleotide polymorphism in the Fas gene. Journal of Endocrinology, 2004, 182, 479-484.	1.2	17
52	Expression and Mutational Status of c-kit in Small-Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 4101-4108.	3.2	87
53	Plasma chromogranin A in incidental non-functioning, benign, solid adrenocortical tumors. European Journal of Endocrinology, 2004, 151, 215-222.	1.9	6
54	Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene, 2004, 23, 5958-5967.	2.6	119

Pinuccia Faviana

#	Article	IF	CITATIONS
55	Plasma and tissue chromogranin in patients with adrenocortical adenomas. Journal of Endocrinological Investigation, 2004, 27, 821-825.	1.8	7
56	Video assisted prophylactic thyroidectomy and central compartment nodes clearance in two RET gene mutation adult carriers. Journal of Endocrinological Investigation, 2004, 27, 557-561.	1.8	28
57	Spontaneous short-term remission of primary hyperparathyroidism from infarction of a parathyroid adenoma. Journal of Endocrinological Investigation, 2004, 27, 687-690.	1.8	16
58	Applications of tissue microarray technology in immunohistochemistry: A study on c-kit expression in small cell lung cancer. Human Pathology, 2004, 35, 1347-1352.	1.1	11
59	Leiomyosarcoma of the popliteal artery: Case report and review of the literature. Journal of Vascular Surgery, 2003, 37, 206-209.	0.6	23
60	Galectin-3 and Oncofetal-Fibronectin Expression in Thyroid Neoplasia as Assessed by Reverse Transcription-Polymerase Chain Reaction and Immunochemistry in Cytologic and Pathologic Specimens. Thyroid, 2003, 13, 765-770.	2.4	51
61	Prevalence of Cancer in Follicular Thyroid Nodules: Is There Still a Role for Intraoperative Frozen Section Analysis?. Thyroid, 2003, 13, 389-394.	2.4	25
62	Simian Virus 40-Like Sequences from Early and Late Regions in Human Thyroid Tumors of Different Histotypes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 892-899.	1.8	29
63	A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. British Journal of Cancer, 2002, 86, 558-563.	2.9	123
64	Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer. International Journal of Oncology, 2002, 20, 155-9.	1.4	10
65	Evaluation of telomerase mRNA (hTERT) in colon cancer. International Journal of Oncology, 2002, 21, 493-7.	1.4	11
66	Small cell lung carcinoma (SCLC): the angiogenic phenomenon. European Journal of Cardio-thoracic Surgery, 2002, 21, 1105-1110.	0.6	124
67	Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying theRET/PTC1 rearrangement. International Journal of Cancer, 2002, 97, 608-614.	2.3	41
68	Neoangiogenesis in colon cancer: Correlation between vascular density, vascular endothelial growth factor (VEGF) and p53 protein expression. Oncology Reports, 2002, 9, 617-20.	1.2	25
69	Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer. Oncogene, 2001, 20, 6632-6637.	2.6	22
70	Regulation of telomerase and its hTERT messenger in colorectal cancer. Oncology Reports, 0, , .	1.2	7
71	p16 and its putative interplay with metabolic factors in prostate cancer: An analysis based on public TCGA data. World Academy of Sciences Journal, 0, , .	0.4	0